Published: Tue, March 13, 2018
People | By Leon Thompson

The Flexion Therapeutics' (FLXN) "Outperform" Rating Reaffirmed at BMO Capital Markets


Berenberg Bank began coverage on Flexion Therapeutics in a research report on Thursday, February 1st. The company was maintained on Monday, June 26 by BMO Capital Markets. (NASDAQ:FLXN) earned "Buy" rating by Cantor Fitzgerald on Wednesday, November 4. RBC Capital Markets maintained D.R. Horton, Inc. (NYSE:DHI) has "Buy" rating given on Thursday, February 1 by Bank of America. The market capitalization of the company is $1.86 Billion. Wells Fargo reinitiated Flexion Therapeutics, Inc. (NASDAQ:FLXN) on Monday, September 11 with "Buy" rating.

BMO Capital Markets reiterated their outperform rating on shares of Flexion Therapeutics (NASDAQ:FLXN) in a research note published on Friday morning. They set a "buy" rating and a $42.00 price target on the stock. As per Wednesday, October 4, the company rating was maintained by Northland Capital. The stock of Flexion Therapeutics, Inc. Thompson Rubinstein Investment Management Inc sold 25,644 shares as the company's stock declined 14.07% while stock markets rallied. Eaton Vance Management now owns 12,900 shares of the specialty pharmaceutical company's stock worth $323,000 after purchasing an additional 3,500 shares during the last quarter. Visteon Corp now has $3.84 billion valuation. About 101,635 shares traded. Visteon Corporation (NYSE:VC) has risen 41.15% since March 12, 2017 and is uptrending. It has outperformed by 105.47% the S&P500.

Stalemate ends in bitter university pensions row
Lecturers' leaders and university officials are said to have reached an agreement in a bitter dispute over pensions. Not everyone is supportive of the deal, however, with some strikers calling for it to be thrown out.

Investors sentiment increased to 3.07 in 2017 Q3. Its down 0.52, from 1.74 in 2017Q2. 22 funds opened positions while 28 raised stakes. The original version of this article can be read at https://stocknewstimes.com/2018/03/11/bamco-inc-ny-grows-position-in-flexion-therapeutics-inc-flxn.html. (NASDAQ:FLXN). Ionic Capital Ltd stated it has 226,964 shares. Moreover, Timpani Capital Mngmt Lc has 0.37% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN) or 107,550 shares. Scholtz & Ltd Co holds 1.05% in Flexion Therapeutics, Inc. Credit Suisse Ag holds 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN) or 55,250 shares. Cantor Fitzgerald maintained Flexion Therapeutics, Inc. (NASDAQ:FLXN). Moreover, Cadence Cap Mngmt Limited Co has 0.08% invested in Flexion Therapeutics, Inc. (NASDAQ:FLXN). 361,349 were accumulated by Northern Tru Corp. (NASDAQ:FLXN) for 144,331 shares. Great West Life Assurance Can has invested 0% in Flexion Therapeutics, Inc. (NASDAQ:FLXN) for 456,384 shares. Lake Street has "Buy" rating and $38 target. California State Teachers Retirement Sys has 44,366 shares for 0% of their portfolio. Alliancebernstein Lp reported 0% of its portfolio in Flexion Therapeutics, Inc. (NASDAQ:FLXN). 800 are held by Northwestern Mutual Wealth Mgmt. The stock of Flexion Therapeutics, Inc. Thompson Rubinstein Investment Management Inc who had been investing in Kemper Corp for a number of months, seems to be less bullish one the $3.02B market cap company. The Company's lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. It now has negative earnings. The stock increased 0.67% or $0.2 during the last trading session, reaching $29.94. The company's stock had a trading volume of 239,527 shares, compared to its average volume of 714,350. Flexion Therapeutics (FLXN) has a 14-day RSI of 60.42, the 7-day is at 62.55, and the 3-day is resting at 49.94. It has outperformed by 65.32% the S&P500. Its the same as in 2017Q2.

Institutional investors have recently added to or reduced their stakes in the stock. Farmers & Merchants Invs reported 236 shares. 850 were reported by Alphaone Investment Ltd Liability Corporation. Proshare Advisors holds 19,877 shares. Twin Tree LP holds 0.01% or 8,426 shares. Investors may also choose to select shares from various industries. Virtus Inv Advisers Inc owns 3,087 shares. 9,983 were reported by Norinchukin Fincl Bank The. Jpmorgan Chase & Co (NYSE:JPM) was reduced too. Two analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. Visteon had 58 analyst reports since August 28, 2015 according to SRatingsIntel. The firm has "Buy" rating given on Monday, July 10 by RBC Capital Markets. The firm has "Buy" rating by Needham given on Wednesday, September 9. FBR Capital maintained Visteon Corporation (NASDAQ:VC) rating on Friday, October 27. On Friday, July 28 the stock rating was downgraded by Gabelli to "Hold". The company was maintained on Thursday, February 15 by Susquehanna. The stock has "Buy" rating by Susquehanna on Thursday, January 4. It is down 25.87% since March 12, 2017 and is downtrending. ANDERSON BRADLEY S had sold 10,000 shares worth $374,629.

Like this: